Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).
Dominick Bosse, MD
Advertisement
Articles by Dominick Bosse, MD
Advertisement
Latest Updated Articles
Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCCPublished: October 10th 2017 | Updated:
Advertisement
Advertisement
